Cashu | News

DJI

-0.77%

SPX

-0.85%

IXIC

-0.96%

FTSE

-0.46%

N225

+0.59%

AXJO

-0.08%

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Company

Help & Support

Legal

Latest Johnson & Johnson News

Peering Into Johnson & Johnson's Recent Short Interest

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Johnson & Johnson denies engaging in illegal DEI practices after group makes civil rights complaint

12 Analysts Have This To Say About Johnson & Johnson

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Health care stocks are due for a turnaround after a historically bad month, according to the charts

Company

Help & Support

Legal

Latest Johnson & Johnson News

Peering Into Johnson & Johnson's Recent Short Interest

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Johnson & Johnson denies engaging in illegal DEI practices after group makes civil rights complaint

12 Analysts Have This To Say About Johnson & Johnson

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Health care stocks are due for a turnaround after a historically bad month, according to the charts

Latest Cashu News

Johnson & Johnson's JNJ-4496 Shows Promise in Treating Aggressive Lymphoma

Johnson & Johnson's Bleximenib Shows Promising Results for Treating Acute Myeloid Leukemia

Johnson & Johnson's TREMFYA® Shows Promising Results for Psoriatic Arthritis Treatment